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Background: Recent reports of the rapid evolution of bacterial resistance in India require 
urgent antibiotic stewardship programs. This study aimed to define the magnitude and pattern 
of resistance of bacterial pathogens to guide empirical therapy.
Methods: We prospectively collected consecutive, clinically significant, and nonduplicate 
bacterial isolates from each patient from two hospitals in Ujjain, India. The antibiotic 
susceptibility of the bacteria was tested using a disc diffusion method as recommended by the 
Clinical and Laboratory Standards Institute.
Results: A total of 716 pathogens were isolated from 2568 patients (median age, 25 years; 
range, 0 days to 92 years). Gram-negative infections were predominant (62%). The isolated 
pathogens included Staphylococcus aureus (n = 221; 31%), Escherichia coli (n = 149; 21%), 
Pseudomonas aeruginosa (n = 127; 18%), and Klebsiella pneumoniae (n = 107; 15%). Common 
diagnoses included abscesses (56%), urinary tract infections (14%), blood stream infections 
(10%), pneumonia (10%), and vaginal infections (10%). In E. coli isolates, 69% (95% confi-
dence interval [CI] 61.6–76.6) were extended-spectrum β-lactamase (ESBL) producers and 41% 
(95% CI 31.6–50.5) of K. pneumoniae isolates were ESBL producers. These isolates had a high 
resistance to fluoroquinolones and β-lactams, except for imipenem and piperacillin-tazobactam. 
Salmonella typhi remained sensitive to third-generation cephalosporins. Methicillin-resistant 
S. aureus (MRSA) constituted 30% of all S. aureus isolates and showed resistance to cipro-
floxacin (81%), cotrimoxazole (76%), and levofloxacin (60%).
Conclusion: Our results showed a high prevalence of ESBL among Gram-negative bacterial 
isolates and a high prevalence of MRSA among S. aureus isolates. Carbapenems provided the 
broadest coverage for Gram-negative bacteria, while glycopeptides were the most effective 
against MRSA; however, both classes of drugs need to be used judiciously. This study will 
help in planning future antibiotic stewardship programs.
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Introduction
Antibiotic resistance is a global public health problem.1,2 The foundation of modern 
medicine is built on the availability of effective antibiotics, especially in economically 
deprived areas of the world where the disease burden due to bacterial infections remains 
high. Antibiotic resistance is predominantly fueled by antibiotic use.3 The regular 
introduction of new antibiotic classes over the years has partly masked the problem of 
increasing resistance. However, this is no longer the case today because the pipeline 
for newer antibiotics is nearly empty.4 Therefore, we need to preserve the currently 
available antibiotics for use by future generations.1,2 The World Health Organization 
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and European Commission have recognized the importance 
of studying the emergence and determination of resistance 
and the need for control strategies. The need for strategies to 
control antibiotic resistance is greater in resource constraint 
settings because antibiotic resistance puts further strain 
on an already fragmented health care system in low and 
middle-income countries.5
One recent eye opener is the spread of Enterobacteriaceae, 
with resistance to carbapenem conferred by New Delhi 
metallo-β-lactamase 1 (NDM-1).6 NDM-1 received extensive 
media coverage for two reasons, ie, the bacteria carrying the 
NDM-1 gene are resistant to all antibiotics except tigecycline 
and colistin, and were rapidly transmitted across national 
borders.6
In India, rapid evolution of bacterial resistance may 
be due to a complex interaction of several factors such as 
higher burden of infectious disease, treatment uncertainty, 
lack of treatment guidelines, inadequate access to standard 
laboratory facilities, self-medication, prescription based on 
availability, government support to pharmaceutical indus-
tries, market forces, antibiotics prescribed by unqualified 
health professionals, less strict law enforcement, fragmented 
public health system, poor population-wide insurance cover-
age, inadequate adherence to universal hygiene and infection 
control measures, and to low population-wide education 
level.7–12 Antibiotic stewardship programs are thus urgently 
needed in India.8,10
Antibiotic susceptibility surveillance is fundamental for 
creating an antibiotic stewardship program. Thus, we set up 
a surveillance system in two hospitals in Ujjain, India, with 
the aim of defining resistance magnitude and patterns of 
bacterial pathogens and providing locally applicable data to 
guide empirical therapy.
Materials and methods
This prospective study was conducted over a period of 
15 months from November 2007 to February 2009 in Ujjain, 
India.
Study settings
The study sites were two hospitals, ie, a 570-bed teaching 
hospital attached to RD Gardi Medical College and a 350-bed 
nonteaching hospital. Both hospitals cater predominantly 
for rural populations from the villages surrounding Ujjain 
city. In both hospitals, most admissions (89%–91%) to the 
medical and intensive care units are made on an emergency 
basis, whereas admissions into surgical units are made on 
an elective or emergency basis.
Collection of samples and study 
participants
We prospectively collected consecutive, nonduplicate, single 
patient samples. Only “clinically significant” samples (from 
patients with presumed infections) were sent for culture. 
The following infections and corresponding samples were 
included in the study: abscesses (pus/secretions and swabs 
from skin and soft tissue infections), post-surgery or traumatic 
wounds, and burns, and ear discharge (in clinically proven 
serous otitis media), urinary tract infections (mid-stream 
clean catch urine or urine from a catheter), blood stream 
infections (in cases of clinical sepsis), pneumonia (induced 
sputum and/or bronchoalveolar lavage), and vaginal infec-
tions (high vaginal swab). Isolates from the screening proce-
dures and samples for fungal, mycobacterial, and anaerobic 
bacterial cultures were not included in the study.
The admitting consultants were requested to send clini-
cally relevant samples for culture from all patients suspected 
of having a bacterial infection. The following demographic 
information was collected for all the patients: age, gender, 
family size, education level (of adult patients or of a child 
patient’s mother), breadwinner’s occupation, reported history 
of antibiotics received in the past two weeks, and reported 
hospitalizations in the past two weeks.
Participating departments in both hospitals included 
pediatrics, general medicine, general surgery, obstetrics 
and gynecology, ear, nose and throat, orthopedics, chest 
medicine, adult medicine intensive care unit, and neonatal 
intensive care unit.
Identification, antibiotic susceptibility 
testing, and definitions of resistance
Within four hours of receipt at the laboratory, all the samples 
were plated on blood agar and MacConkey agar medium 
(HiMedia Laboratories Pvt, Ltd, Mumbai, India). Pathogenic 
bacteria were identified using standard conventional micro-
biological methods.13 Antibiotic sensitivity testing was 
performed using the Kirby-Bauer disc diffusion method 
on Mueller-Hinton agar plates. The disc strengths were as 
recommended by the Clinical and Laboratory Standards 
Institute (CLSI) at the time of the study. CLSI interpretive 
criteria for susceptibility and resistance were followed.14 
Antibiotic sensitivity testing quality control was performed 
using the following reference strains: Escherichia coli ATCC 
(American Type Culture Collection) 25922, Klebsiella 
pneumoniae ATCC 70063, Pseudomonas aeruginosa 
ATCC 27853, Enterococcus faecalis ATCC 29212, and 
Staphylococcus aureus ATCC 29213. Intermediate sensitive 
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isolates of Gram-negative bacteria were counted as resistant 
in the calculations.
Extended-spectrum β-lactamase (ESBL) production was 
detected using a double-disc synergy test.15 The presence 
of ESBL was assayed using the following antibiotic discs: 
cefotaxime 30 µg, cefotaxime/clavulanic acid 30/10 µg, 
ceftazidime 30 µg, and ceftazidime/clavulanic acid 30/10 µg 
(HiMedia Laboratories Pvt, Ltd, Mumbai, India). According to 
the CLSI criteria for ESBL detection, each isolate with an inhi-
bition zone diameter of #22 mm for ceftazidime or #27 mm 
for cefotaxime was considered to be a potential ESBL pro-
ducer or screen positive. A zone diameter increase of $5 mm 
for either antimicrobial agent when tested in combination with 
clavulanic acid versus when tested alone was considered as 
an ESBL-producing organism. K. pneumoniae ATCC700603 
(positive control) and E. coli ATCC25922 (negative control) 
were used for quality control in the ESBL tests.14
For S. aureus isolates, screening for methicillin resistance 
was performed using a cefoxitin disc screen test and 6 g/mL 
oxacillin in Mueller-Hinton agar supplemented with NaCl 
(4% w/v; 0.68 mol/L) according to the CLSI guidelines.14 
Multidrug-resistant isolates were defined as isolates having 
coresistance to at least three antibiotic groups.16 The ethics 
committee of RD Gardi Medical College approved the study 
(approval number 41/2007). The cultures were performed 
without any cost to the patients, and the results were made 
available to each patient’s physician.
Statistical analysis
The data were entered in EpiData Entry (version 3.1) software 
and then transferred to Stata 10.0 for further analysis (Stata 
Corporation, College Station, TX). Descriptive statistics 
were used.
Results
Patient demographics and distribution 
within departments or wards
The main characteristics of patients enrolled in the study 
are shown in Table 1. A total of 716 pathogens were isolated 
from 2568 patients. Thus, the culture positivity rate was 
28% (95% confidence interval [CI] 26.1–29.6). The median 
patient age was 25 (range, from 0 days to 92 years), and 
the median age of men and women was 23 and 26 years, 
respectively. Most samples (95%) were sent from wards while 
the remaining samples were sent from intensive care units. 
The most common diagnoses (Table 2) were abscesses (56%), 
urinary tract infections (14%), blood stream infections (10%), 
  pneumonia (10%), and vaginal infections (10%).
Most common pathogens
The distribution of the four most common pathogens by infec-
tion site is shown in Table 2. Details of site of infection and pro-
portion of different bacteria (n = 393) isolated from abscesses 
are shown in Figure 1. Gram-negative infections were predomi-
nant (62%). However, the most commonly isolated pathogen 
was S. aureus (n = 221; 31%), followed by E. coli (n = 149; 
21%), P . aeruginosa (n = 127; 18%), and K. pneumoniae 
(n = 107; 15%). S. typhi was isolated most frequently from 
blood stream infections (21%). E. coli constituted 66% of the 
urinary tract infection isolates. In pneumonia, P . aeruginosa 
was the most commonly isolated organism (n = 22; 30%), 
Table 1 Demographic characteristics of the 901 pediatric and 
1667 adult patients from whom 716 pathogenic bacteria were 
isolated in Ujjain, India
Patient  
characteristics
Pediatrics  
(0–12 years)
Adults Total 
(%)
n = 901  
(35%)
n = 1667  
(65%)
n = 2568  
(100%)
Gender 
Male 
Female
 
569 (63) 
332 (37)
 
868 (52) 
799 (48)
 
1437 (56) 
1131 (44)
Family size 
#4 
5–10 
.10
 
356 (40) 
502 (55) 
43 (5)
 
742 (44) 
778 (47) 
147 (9)
 
1098 (43) 
1280 (50) 
190 (7)
Hospital 
Nonteaching 
Teaching
 
552 (58) 
379 (42)
 
608 (36) 
1059 (64)
 
1130 (44) 
1438 (56)
Hospital ward 
Pediatrics 
Medicine 
Obstetrics and  
gynecology 
Surgery 
Orthopedics 
ENT 
Chest medicine 
NICU 
PICU 
ICU 
Others
 
686 (76) 
– 
14 (2) 
 
38 (4) 
10 (1) 
69 (8) 
7 (0.7) 
62 (7) 
12 (1) 
– 
3 (0.3)
 
– 
243 (14) 
378 (23) 
 
661 (40) 
37 (2) 
150 (9) 
103 (6) 
– 
– 
46 (3) 
49
 
686 (27) 
243 (9) 
392 (15) 
 
699 (27) 
47 (2) 
219 (7.5) 
110 (4) 
62 (2) 
12 (0.5) 
46 (2) 
52 (2)
Source of infection
Abscesses 
Pneumonia 
UTI 
BSI 
Vaginal infections
151 (17) 
480 (53) 
75 (8) 
182 (20) 
13 (1)
770 (46) 
257 (15) 
331 (20) 
72 (4) 
237 (14)
921 (36) 
737 (29) 
406 (16) 
254 (10) 
250 (10)
Gram-negative  
bacteria grown
88 (53) 359 (65) 447 (62)
Gram-positive  
bacteria grown
77 (47) 192 (35) 269 (38)
Abbreviations:  ENT,  ear  nose  and  throat;  NICU,  neonatal  intensive  care  unit; 
PICU, pediatric intensive care unit; ICU, intensive cardiac care unit; UTI, urinary tract 
infection; BSI, blood stream infection.
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f  ollowed by K. pneumoniae (n = 21; 28%) and S. aureus 
(n = 10; 14%). Gram-negative organisms were isolated from 
the bronchoalveolar lavage samples from adults or from the 
pneumonia with sepsis samples from neonates. Gram-negative 
E. coli, K. pneumoniae, and P . aeruginosa constituted 75% of 
the organisms isolated from vaginal infection.
Antibiotic susceptibility testing  
of common Gram-negative bacteria
A total of 447 Gram-negative pathogens were isolated. 
The in vitro antibiotic susceptibility of the common 
Gram-negative bacteria is shown in Table 3. Remarkably 
high resistance for β-lactam antibiotics (range 72%–97%) 
and fluoroquinolones (range 51%–95%) was observed 
for the three most common Gram-negative bacteria, ie, 
E. coli, P . aeruginosa, and Klebsiella. E. coli showed the 
highest susceptibility (98%) to imipenem followed by 
piperacillin-tazobactam (85%). The same antibiotics were 
also active against other Enterobacteriaceae, Klebsiella, 
Pseudomonas, and Proteus species. S. typhi showed good 
sensitivity to the third-generation cephalosporins, ie, 
ceftriaxone (86%) and ceftazidime (88%), as compared 
with fluoroquinolones, ie, ciprofloxacin (31%) and ofloxacin 
(28%, Table 3).
The ESBL rates were 69% (95% CI 61.6–76.6) for 
E. coli and 41% (95% CI 31.6–50.5) for K. pneumoniae. 
Among E. coli, P . aeruginosa, and Klebsiella, coresistance 
to cephalosporins and fluoroquinolones was 51.2% (95% CI 
44.8–58.3). The multidrug-resistant rate among Gram-negative 
bacteria was 17.6% (95% CI 14.1–21.2). The multidrug-resis-
tant rates were highest for E. coli (21%; 95% CI 14.8–28.1), 
followed by K. pneumoniae (19%; 95% CI 11.1–26.1) and 
P . aeruginosa (17%; 95% CI 9.9–23.0). There were three 
pan-resistant isolates (for the tested antimicrobial drugs), one 
each for E. coli, P . aeruginosa, and K. pneumoniae.
Antibiotic susceptibility testing  
of common Gram-positive bacteria
The in vitro antibiotic susceptibility pattern of 154 methicillin-
sensitive S. aureus (MSSA) isolates is shown in Table 4. 
Resistance to commonly used oral antibiotics, including 
ampicillin (86%), amoxicillin-clavulanate (50%), cotrimox-
azole (38%), ciprofloxacin (49%), and erythromycin (9%) 
was noted in MSSA isolates. Because physicians commonly 
coprescribe amikacin in our study setting to treat serious 
S. aureus infections, we studied coresistance of S. aureus to a 
combination of amikacin with different classes of antibiotics. 
Coresistance for amikacin was observed for ampicillin 
(6%), amoxicillin-clavulanate (5%), ciprofloxacin (4%), 
ceftriaxone (1%), and chloramphenicol (1%). Coresistance 
to ciprofloxacin and erythromycin was 7%.
MSSA isolates did not show resistance to vancomycin, 
teicoplanin, linezolid, or clarithomycin. However, high 
susceptibility was also noted for cefoxitin (93%), amikacin 
(94%), clindamycin (92%), gentamicin (90%), and 
chloramphenicol (86%).
MRSA constituted 30% of all S. aureus isolates. The 
antibiotic susceptibility pattern of the 67 MRSA isolates is 
shown in Table 4. The MRSA isolates showed resistance 
Table 2 Distribution of commonest four pathogens per site of 
infection in surveillance study in two hospitals, Ujjain, India
Site of infection n % of total Rank
Abscessa
Staphylococcus aureus 185 47 1
Pseudomonas aeruginosa 84 21 2
Klebsiella pneumoniae 44 11 3
Escherichia coli 43 11 4
Others 37 10 –
Total 393 100
UTIb
Escherichia coli 61 60 1
Klebsiella pneumoniae 25 24 2
Pseudomonas aeruginosa 6 5 3
Bacillus spp. 3 3 4
Others 8 8 –
Total 103 100
BSIc
Salmonella typhi 21 28 1
CoNS 20 27 2
Staphylococcus aureus 10 13 3
Pseudomonas aeruginosa 6 8 4
Others (Escherichia coli, 8 isolates) 18 24 –
Total 75 100
Pneumoniad
Pseudomonas aeruginosa 22 30 1
Klebsiella pneumoniae 21 28 2
Staphylococcus aureus 10 14 3
Escherichia coli 8 8 4
Others 15 20 –
Total 74 100
Vaginal infectionse
Escherichia coli 32 45 1
Staphylococcus aureus 14 20 2
Klebsiella pneumoniae 12 17 3
Pseudomonas aeruginosa 9 13 4
Others 4 5 –
Total 71 100
Notes: aIncluding pus/secretions and swabs from skin and soft tissue infections, post-
surgery or traumatic wounds, burns, ear discharge (clinically confirmed otitis media), 
empyema, breast abscess and intra-abdominal abscess (See Figure 1 for details); 
bUTI urinary tract infection; most (91%) samples were mid-stream clean catch and 
the rest urine from catheter;  cBSI blood stream infections; samples sent in cases 
of clinical sepsis; dpneumonia samples were induced sputum and bronchioalveolar 
lavage; evaginal infection samples were high-vaginal swabs.
Abbreviations: BSI, blood stream infection; CoNS, coagulase-negative staphylococci; 
UTI, urinary tract infection.
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to ciprofloxacin (81%), cotrimoxazole (76%), levofloxacin 
(60%), erythromycin (28%), and doxycycline (27%). 
Moreover, MRSA showed coresistance to levofloxacin 
and amikacin (27%), doxycycline and levofloxacin (27%), 
ciprofloxacin and amikacin (24%), ciprofloxacin and 
erythromycin (22%), doxycycline and amikacin (16%), and 
chloramphenicol with amikacin (9%). No resistance was 
noted for clindamycin and amikacin.
Coagulase-negative staphylococci (n = 20) were 
regarded as pathogens after considering the clinical con-
dition of a patient and when cultured in paired blood 
samples. Methicillin resistance was 89%. A high proportion 
of resistance was observed for chloramphenicol (88%), 
cotrimoxazole (82), tetracycline (76%), doxycycline (68%), 
and clindamycin (54%).
Discussion
To the best of our knowledge, this is the first surveillance 
study that examined the antimicrobial susceptibilities of 
common pathogens in a rural resource-poor setting in central 
India. In India, most populations reside in and seek health 
care in similar settings. However, previously reported stud-
ies have been performed in larger metropolitan cities.11,12 
The present study showed that the common pathogens 
were S. aureus (31%), E. coli (21%), P . aeruginosa (18%), 
and K. pneumoniae (15%). The ESBL rate of E. coli was 
69% (95% CI 61.6–76.6), while that of K. pneumoniae 
was 41% (95% CI 31.6–50.5). MRSA constituted 30% of 
all S. aureus isolates. To improve the clinical outcome of 
patients in resource-poor settings, treatment guidelines for 
empirical therapy need to be formulated. These guidelines 
should ideally be aligned with local susceptibility patterns. 
Availability of this information will help clinicians select 
appropriate and effective therapy and reduce the incidence 
of drug-resistant bacteria.
In this study, abscesses, pneumonia, and urinary tract 
infection were responsible for 80% of all the culture-
positive infections. E. coli, P . aeruginosa, K. pneumoniae, 
and S. aureus were responsible for 85% of culture-positive 
infections. Similar patterns of bacterial isolates are noted from 
other resource-constrained countries,17,18 including India.11,12 
The SENTRY Antimicrobial Surveillance Program in the 
Asia-Pacific also reported S. aureus as the most common 
organism, followed by P . aeruginosa and E. coli.19,20
P . aeruginosa was the most common organism isolated 
from pneumonia and the second most common organism 
isolated from abscesses. It remains the leading cause of 
health care-associated infections worldwide, especially 
50%
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Figure 1 Details of site of infection and proportion of different bacteria (n = 393) isolated from abscesses in two hospitals in Ujjain, India.
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in patients admitted to intensive care units. The organism 
is ranked second only to S. aureus as the most common 
cause of health care-associated infections in most European 
intensive care units.21 A single tertiary care center reported 
a three-fold increase in the number of P . aeruginosa isolates 
in India during the study period of 2007–2008 along with 
decreasing sensitivity to meropenem (from 64% in 2007 to 
35% in 2008).11 Decreasing sensitivity to third-generation 
cephalosporins and fluoroquinolones is also well established 
in India.11,12 Most of the isolates of P . aeruginosa in the pres-
ent study could be from health care-associated infections. The 
susceptibility rates found in the present study (13% for cef-
tazidime, 37% for ciprofloxacin) are similar to those observed 
in other studies from India.22,23 Varghese et al12 reported 70% 
resistance to fluoroquinolones and other second-line antip-
seudomonal drugs such as piperacillin/tazobactam (42%), 
cefoperazone/sulbactam (40%), and cefpirome (54%).
The third generation cephalosporins effective against 
Pseudomonas aeruginosa are ceftazidime and cefaperazone. 
Nearly 87% of the isolates in this study are resistant to 
Ceftazidime. This may be a local phenomenon.
Carbapenems, colistin, polymyxin B, or a combination 
of ceftazidime and an aminoglycoside can be used for 
the empirical treatment of Pseudomonas infections.11,24 
Increasing carbapenem resistance is a global challenge,20 but, 
fortunately, the phenomenon is rare in our setting.
Widespread resistance of S. typhi to commonly used 
oral antibiotics is a serious clinical and a public health 
challenge. In the present study, S. typhi showed high resis-
tance to ampicillin, cotrimoxazole, and ciprofloxacin. This 
phenomenon has been reported in other studies, discussed 
in a recent review,25 which suggested that fluoroquinolones 
and third-generation cephalosporins are equally effec-
tive treatment options for Salmonella infections.25 In the 
present study, however, the sensitivity to third-generation 
cephalosporins remained high (86%–88%), indicating 
that they are a better treatment option than fluoroquino-
lones. However, minimum inhibitory concentrations for 
Table 3 Spectrum of activity of 20 antimicrobials against five most prevalent causes of Gram-negative infections in a surveillance study 
in two hospitals, Ujjain, India
Antimicrobial class/agent  
tested
Resistance by organism (number tested)
R (%)
E. coli 
(149)
P. aeruginosa 
(127)
K. pneumoniae 
(107)
S. typhi 
(21)
Proteus spp. 
(20)
Penicillin 
Ampicillin 
Amoxicillin/clavulanate 
Piperacillin/tazobactam
 
89 
82 
15
 
 
 
17
 
97 
90 
21
 
87 
 
 
80 
79 
12
Cephalosporins 
Cefuroxime 
Ceftriaxone 
Cefixime 
Cefpodoxime 
Ceftazidime
 
80 
72 
79 
79 
73
 
 
 
 
 
87
 
93 
79 
 
75 
82
 
 
14 
 
 
 
76 
74 
72 
75 
74
Other β lactam 
Imipenem
 
2
 
2
 
2
 
0
 
0
Quinolones 
Nalidixic acid 
Ciprofloxacin 
Norfloxacin 
Ofloxacin 
Gatifloxacin 
Sparfloxacin
 
92 
83 
85 
80 
79 
80
 
 
63 
 
55 
64 
61
 
93 
65 
74 
55 
53 
51
 
83 
69 
– 
72 
 
 
82 
71 
70 
68 
67 
72
Aminoglycosides 
Gentamicin 
Amikacin
 
59 
33
 
69 
38
 
69 
32
 
 
 
33 
20
Others 
Chloramphenicol 
Tetracycline 
Cotrimoxazole 
Nitrofurantoin
 
33 
92 
83 
12
 
 
 
 
–
 
 
 
94 
–
 
2 
 
87 
–
 
50 
100 
58 
–
Abbreviation: R, resistance.
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fluroquinolones and third-generation cephlosporins would 
better guide therapy.
It is widely accepted that the first-line empirical treatment for 
uncomplicated urinary tract infection should be cotrimoxazole 
if resistance rates of urinary E. coli to cotrimoxazole are ,20%. 
If cotrimoxazole resistance is .20%, fluoroquinolone, 
nitrofurantoin, or fosfomycin are recommended.26 In the 
present study, resistance to cotrimoxazole was documented 
to be .80%, which is in accordance with the high-resistance 
rates recorded in other Indian studies.27 Most patients at the 
two study sites were treated with norfloxacin in outpatient 
clinics.28 Because quinolones select more antibiotic-resistant 
strains and nitrofurantoin shows good activity against E. coli, 
nitrofurantoin would serve as better alternative first-line drug 
for the treatment of uncomplicated urinary tract infection 
in this setting. However, nitrofurantoin is not aggressively 
marketed and has supply-related problems. Treatment 
options for complicated urinary tract infection need to be 
individualized based on culture reports.
ESBL production was 69% in E. coli isolates and 41% in 
K. pneumoniae isolates. The above pattern of resistance is a 
clue toward other possible mechanisms of resistance, includ-
ing AmpC production. Studies performed in India have shown 
that plasmid-borne and chromosomally mediated AmpC- 
and cephalosporinase-producing pathogens are common in 
resistant E. coli and K. pneumoniae isolates.22,29 The reported 
prevalence of ESBL-producing Gram-negative isolates in 
various hospitals in India is in the range of 19%–60%.22
Table 4 Spectrum of activity of 25 antimicrobials against three most prevalent causes of Gram-positive infections in surveillance study 
in two hospitals, Ujjain, India
Antimicrobial class/agent  
tested
Activity by organism (number tested)
MSSA (154) MRSA (67) CoNS (20)
R (%) IR (%) S (%) R (%) IR (%) S (%) R (%) IR (%) S (%)
Penicillin 
Oxacillin 
Ampicillin 
Amoxicillin/clavulanate
 
– 
86 
50
 
– 
– 
2
 
100 
14 
48
 
100 
– 
–
 
– 
– 
–
 
– 
– 
–
 
89 
– 
42
 
– 
– 
–
 
11 
– 
58
Cephalosporins 
Cefoxitin 
Ceftriaxone 
Cefixime 
Cefoperazone
 
4 
3 
32 
49
 
3 
3 
3 
8
 
93 
94 
65 
43
 
*
 
*
 
*
 
*
 
*
 
*
Quinolone 
Ciprofloxacin 
Ofloxacin 
Gatifloxacin 
Sparfloxacin 
Levofloxacin 
Lomefloxacin
 
49 
34 
22 
30 
29 
38
 
3 
2 
4 
3 
6 
2
 
48 
64 
74 
67 
65 
60
 
81 
63 
58 
60 
60 
67
 
1 
6 
13 
3 
6 
–
 
18 
31 
29 
37 
34 
33
 
58 
– 
– 
– 
60 
–
 
3 
– 
– 
– 
2 
–
 
49 
– 
– 
– 
48 
–
Macrolides-lincosamides
Erythromycin 
Clarithromycin 
Clindamycin
9 
– 
4
10 
– 
4
81 
100 
92
28 
9 
21
16 
– 
7
56 
91 
72
68 
– 
56
2 
– 
–
32 
– 
44
Glycopeptides 
Vancomycin 
Teicoplanin
 
– 
–
 
– 
–
 
100 
100
 
2 
–
 
– 
–
 
98 
100
 
– 
–
 
– 
–
 
100 
100
Aminoglycosides 
Gentamicin 
Amikacin
 
8 
6
 
1 
2
 
91 
92
 
34 
24
 
2 
2
 
64 
74
 
– 
38
 
– 
–
 
– 
62
Other classes 
Lenezolid 
Chloramphenicol 
Tetracycline 
Doxycycline 
Cotrimoxazole
 
– 
13 
21 
18 
38
 
– 
1 
4 
4 
4
 
100 
86 
75 
78 
58
 
– 
15 
30 
27 
76
 
– 
5 
4 
2 
1
 
100 
80 
66 
71 
23
 
50 
88 
76 
68 
82
 
– 
– 
– 
2 
1
 
50 
12 
24 
30 
17
Notes: CoNS were considered only in the blood stream infections if the clinical condition of the patient merited it, Resistant (R) and susceptible (S) percentage as per CLSI 
criteria 2006. *See the oxacillin results for rates of susceptibilty.
Abbreviations: IR, Intermediate resistant; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; CLSI, Clinical and Laboratory 
Standards Institute; CoNS, coagulase-negative Staphylococcus aureus; R, resistance.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
71
Antibiotic susceptibility of pathogens in IndiaInfection and Drug Resistance 2012:5
Prevalence of ESBL-producing Gram-negative isolates 
in various hospitals in India is in the range of 19%–60%. 
Cabapenem resistance is reported to be 5.3%–59% in various 
metropolitan tertiary care hospitals22
A study performed in a tertiary care hospital in 
Hyderabad by Subbalaxmi et al11 showed that only 8% E. 
coli isolates were sensitive to ceftriaxone, a frequently used 
empirical antibiotic. Sensitivity to a combination of β-lactam 
β-lactamase inhibitors like cefaperazone/sulbactam and 
piperacillin/tazobactam was 59% and 61%, respectively. This 
study showed a high prevalence of ESBL in an urban set-up.11 
A high prescribing rate of fluroquinolones was documented 
in an outpatient study on antibiotic prescribing linked with 
diagnosis in the same settings.28 The rate of fluoroquinolone 
use determines the resistance rates for both fluoroquinolones 
and third-generation cephalosporins.30 This finding might 
explain the high rate of coresistance (51.2%) to third-
generation cephalosporins and ciprofloxacin documented in 
the present study.
Among the Gram-positive organisms, S. aureus and 
coagulase-negative staphylococci were the most common 
organisms. MRSA constituted 30% of all S. aureus isolates. 
The antibiotic susceptibility pattern of MRSA showed 
resistance to commonly used antibiotics, which has been 
documented in Southeast Asia17,18 and India.11,12 Varghese 
et al12 in an Indian study performed at a tertiary care center in 
Manipal reported a MRSA rate of 35%. Increased resistance 
of MRSA isolates to almost all antibiotics over a one-year 
period was observed in this study.12 They reported a high 
proportion of resistance of MRSA isolates to the commonly 
used first-line antibiotics, such as cotrimoxazole (96%), 
ciprofloxacin (85%), erythromycin (83%), and tetracyclines 
(72%). Our results showed better susceptibility to the above 
antibiotics except ciprofloxacin. These differences in the 
results could be due to the differences in geographical areas 
and settings. The resistance rates for ciprofloxacin in the two 
studies are quite similar (81% in our study versus 85% in the 
referenced study).12 This finding could be because of high 
outpatient use of quinolones in our settings.28 Other hospitals 
(predominantly urban) in India have reported MRSA rates 
of 8%–71%.22
The main strength of this survey is that it provides much 
needed data for evidence-based discussion on prudent anti-
biotic prescribing in India. The data have links to clinical 
infections, information that is usually minimal or absent in 
laboratory-based studies. Our study has limitations. Because 
of the limited sample size, we were unable to detect uncom-
mon forms of resistance, such as carbapenem resistance and 
vancomycin-resistant enterococci. The “gold standard” for 
antibiotic susceptibility reporting is minimum inhibitory con-
centration testing; this was not performed because we wanted 
to perform the tests that are normally available in this type of 
setting. Hospitalization durations were not recorded; thus, it 
was not possible to distinguish between health care-associated 
infections and community-acquired infections. The likelihood 
that the isolated organism is a colonizing bacterium should 
be considered in such studies. However, in the present study, 
because the inclusion criterion was a patient with a suspected 
infection, this possibility was minimized.
Conclusion
In conclusion, this is the first surveillance study of antimi-
crobial susceptibility performed in a rural resource-poor 
setting in central India. The results define the occurrence of 
pathogens and suggest the leading antimicrobial resistance 
mechanisms. Carbapenems provide the broadest coverage for 
Gram-negative bacteria and glycopeptides are most effective 
against MRSA; however, both these classes of drugs need to 
be used judiciously. Antimicrobial resistance surveillance is 
necessary for both day-to-day clinical decisions and to reflect 
local, regional, and national trends. Comprehensive surveil-
lance programs linked to antimicrobial prescription need to 
be prioritized to set up effective infection control measures. 
The data from this study will be useful for planning antibiotic 
stewardship programs in India.
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